Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists identify prostate cancer stem cells among low-PSA cells

07.05.2012
Cells resist hormone inhibition and chemotherapy; video captures production of other cell types

Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.

"Using a new technique, we were able for the first time to separate low-PSA and high-PSA prostate cancer cells. This led to the discovery of a low-PSA population of cancer stem cells that appears to be an important source of castration-resistant prostate cancer," said study senior author Dean Tang, Ph.D., professor in MD Anderson's Department of Molecular Carcinogenesis.

Hormone therapy is used to block production of testosterone, which fuels prostate cancer growth, via either chemical or physical castration. Tumors eventually resist this approach.

In cell lines and mouse model experiments, the low-PSA cells resisted chemotherapy and thrived under hormone deprivation, the two main prostate cancer drug treatments , the researchers found.

Low-PSA cells were found to be both self-renewing and capable of differentiating into other prostate cancer cell types upon division, a hallmark of stem cells called asymmetric cell division.

"Asymmetric cell division is the gold standard feature of normal stem cells," Tang said. "Using time-lapse fluorescent microscopy, we were able to show asymmetric cell division by filming a low-PSA cell dividing into one high-PSA cell and one low-PSA cell."

Their findings point to the need to develop new therapeutics to target low-PSA prostate cancer cells that can be combined with hormone therapy to wipe out cancer cells and prevent recurrence.

Low-PSA tumors associated with advanced prostate cancer

Previous research by others indicated that low-PSA tumor cells are rare in early stage disease but become more abundant in advanced prostate cancer. And patients whose tumors were composed of more than 50 percent PSA-positive cells enjoyed longer survival.

This made Tang and colleagues wonder whether the two cell types fundamentally differ from each other and so play different roles in prostate cancer progression.

They analyzed 20 untreated prostate cancer samples staged at varying degrees of aggressiveness on the Gleason scale and 23 samples where treatment had failed. High-PSA tumor cells composed on average about 80 percent of the Gleason 7 tumors, about 60 percent of the higher grade Gleason 9/10 tumors but only about 15 percent of the treatment-failed tumors.

A database analysis of gene expression in prostate cancer was consistent with the tumor experiments, indicating an association between low levels of PSA in tumors and disease recurrence, spread to lymph nodes, metastasis and shortened patient survival.

Turning high-PSA cells green

The next challenge was separating the two cell types to understand their biological, tumor-initiating and drug-response properties.

Tang and colleagues developed a lentiviral delivery system equipped with a PSA promoter that triggers green fluorescence protein when PSA is expressed in an infected cell.

This lentiviral reporter system allowed separation of low-PSA and high-PSA cells for the first time, Tang said. A series of experiments uncovered striking differences between them.

High-PSA prostate cancer cells:
Divide rapidly, which makes them vulnerable to chemotherapy that targets fast-proliferating cells;

Express high levels of the androgen receptor, a key to testosterone production, and so are vulnerable to hormonal therapy; and

Produce only identical copies of themselves when they divide.


Low-PSA prostate cancer cells:
Divide slowly and express anti-stress genes that help them resist chemotherapy;

Either lack or have a weak presence of the androgen receptor, allowing them to grow while hormonal therapy wipes out PSA-positive cells; and

Can divide into one copy of themselves and one PSA-positive cell during reproduction. The researchers captured this on video microscopy, filming the division of a grey low-PSA cell into one copy of itself and one copy of a vibrantly green PSA-positive cell.


Low-PSA tumors have long-term tumor-generating capacity

When the team implanted the two cell types in hormonally intact male mice, the rapidly reproducing PSA-positive cells caused faster growth and larger tumors in the first generation. However, after that the low-PSA cells generated larger, faster-growing tumors and tumor incidence in the high-PSA cells dropped. In fact, the low-PSA prostate cancer cells possess indefinite tumor-propagating capacity.

In contrast, when implanted in the castrated mice, the low-PSA prostate cancer cells developed much larger tumors than the corresponding high-PSA cells. In another experiment, mice with tumors generated by either cell type were then castrated and treated with hormonal therapy. Low-PSA tumors grew better in these doubly androgen-deprived mice than the high-PSA tumors.

"These findings closely resemble progression observed in patients after androgen-deprivation treatment and reflect reducedPSA-producing cells in patient tumors after androgen depletion," Tang said.

Effect of low-PSA cells in human tumors

Tang and colleagues analyzed tumor cell PSA expression in 556 human tumors and found low protein levels correlated with reduced overall survival.

They separated the two types of cells in three primary human tumors and found that low-PSA cells did not express androgen receptor and have higher cell-generating and sphere-forming capabilities than high-PSA cells.

Future research will focus on developing therapeutic targets for low-PSA cells and illuminating the epigenetic landscapes of both cell types.

Co-authors with Tang are co-first authors Jichao Qin, Ph.D., and Xin Liu, Ph.D., Brian Laffin, Ph.D., Xin Chen, M.D., Grace Choy, Ph.D., Collene Jeter, Ph.D., Tammy Calhoun-Davis, Hangwen Li, Ph.D., Kevin Lin, and Mahipal Suranen, Ph.D., all of MD Anderson's Department of Molecular Carcinogenesis at the Science Park in Smithville, Texas; Ganesh Palapattu, M.D., The Methodist Hospital, Houston; Shen Pang, Ph.D., UCLA Dental Research Institute and School of Dentistry; Jiaoti Huang, M.D.,Ph.D., UCLA David Geffen School of Medicine; Ivan Ivanov, Ph.D., Texas A&M University College of Veterinary Medicine; and Wei Li, Ph.D., Baylor College of Medicine, Houston.

This research was financed by grants from the National Cancer Institute, the U.S. Department of Defense, the Cancer Prevention and Research Institute of Texas, the Elsa Pardee Foundation, the MD Anderson Cancer Center University Cancer Fund, MD Anderson Center for Cancer Epigenetics, the Laura and John Arnold Foundation RNA Center and MD Anderson's Cancer Center Support Grants.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory

nachricht Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>